- Home
- ACT vs TFX Comparison
ACT vs TFX Comparison
Compare ACT & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACT
- TFX
- Stock Information
- Founded
- ACT 1981
- TFX 1943
- Country
- ACT United States
- TFX United States
- Employees
- ACT N/A
- TFX N/A
- Industry
- ACT Specialty Insurers
- TFX Medical/Dental Instruments
- Sector
- ACT Finance
- TFX Health Care
- Exchange
- ACT Nasdaq
- TFX Nasdaq
- Market Cap
- ACT 5.5B
- TFX 5.1B
- IPO Year
- ACT 2021
- TFX N/A
- Fundamental
- Price
- ACT $38.91
- TFX $130.32
- Analyst Decision
- ACT Hold
- TFX Hold
- Analyst Count
- ACT 3
- TFX 9
- Target Price
- ACT $39.67
- TFX $141.57
- AVG Volume (30 Days)
- ACT 316.0K
- TFX 566.9K
- Earning Date
- ACT 11-05-2025
- TFX 10-30-2025
- Dividend Yield
- ACT 2.14%
- TFX 1.04%
- EPS Growth
- ACT 6.06
- TFX N/A
- EPS
- ACT 4.41
- TFX 4.18
- Revenue
- ACT $1,223,030,000.00
- TFX $3,041,342,000.00
- Revenue This Year
- ACT $4.10
- TFX $10.16
- Revenue Next Year
- ACT $3.52
- TFX $10.10
- P/E Ratio
- ACT $8.89
- TFX $31.37
- Revenue Growth
- ACT 3.15
- TFX 1.11
- 52 Week Low
- ACT $30.79
- TFX $108.90
- 52 Week High
- ACT $39.47
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- ACT 61.59
- TFX 60.05
- Support Level
- ACT $38.12
- TFX $128.32
- Resistance Level
- ACT $39.47
- TFX $133.18
- Average True Range (ATR)
- ACT 0.66
- TFX 2.62
- MACD
- ACT 0.03
- TFX 0.12
- Stochastic Oscillator
- ACT 77.95
- TFX 69.51
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.